Care pathways & referral

WHO is preparing to ration the obesity drug revolution before it becomes another access disaster

AML’s Frontline Future Starts With Finding the Mutation Fast

Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems

Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem

Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology

AMR Stewardship Starts Before the Antibiotic Is Prescribed

HEARTS 2.0: Latin America moves beyond hypertension and into cardio-kidney-metabolic care

GIST Care Looks Beyond First-Generation KIT Control

Pancreatic Cancer Finally Gets a RAS Moment
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
